Research
Hormonal
Phenotype-guided treatment selection (matching drug mechanism to obesity subtype like 'hungry brain' or 'slow burn') results in significantly greater weight loss compared to standard care.
Ask your doctor about your obesity phenotype (e.g., 'hungry brain', 'slow burn'). Matching your medication to your specific metabolic or behavioral drivers can nearly double your weight loss success compared to standard treatment approaches.
GoodSupportsHIGH confidence
Patients who received treatment tailored to their phenotype achieved significantly greater weight loss after 12 months compared to those receiving standard care (15.9% vs. 9.0%, respectively).
Why this rating
Based on a comparative study cited in the review showing significant difference (p < 0.001 implied by 'significantly greater').
Source
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Michał Nicze et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27062539
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP1R gene polymorphisms (specifically rs10305420 and rs6923761) significantly predict differential weight loss responses to GLP-1 receptor agonists like liraglutide, with certain variants linked to poor anti-obesity response.Good
- The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →